Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Anticancer pharmaceutical application of glufosfamide

A technology of glufosfamide and cancer, applied in the field of glufosfamide, can solve the problems such as no development and listing, no significant increase in overall survival rate, etc.

Inactive Publication Date: 2019-06-04
SHENZHEN ASCENTAWITS PHARM TECH CO LTD
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] US Threshold company obtained the US FDA's fast-track approval qualification in 2004 for the treatment of unresectable locally advanced or metastatic pancreatic cancer that has previously received gemcitabine (W.Steve Ammons, Jin-Wei Wang y, Zhijian Yang y, George F.Tidmarshz and Robert M.Hoffmany, Neoplasia, 2007.8,9(8):625-633), but in 2007 the company announced that there was no significant increase in phase III clinical trials for patients with metastatic pancreatic cancer as second-line treatment Overall survival (Tudor E. Ciuleanua, Alexander V. Pavlovskyb, Gyorgy Bodokyc, Avgust M. Garind, Virginia K. Langmuire, Stewart Krolle, George T. Tidmarshe, Arandomised Phase III trial of glufosfamide compared with best supportive care in metastatic remapped with gemcitabine, European Journal Of Cancer, 45(2009):1589-1596), that is, the subsequent development of the drug ended in failure because the final phase III clinical trial failed
[0005] In China, Qilu Pharmaceutical Co., Ltd. and Jiangsu Hansoh Pharmaceutical Co., Ltd. also applied for new drugs in 2005, and obtained approval from China Food and Drug Administration. However, there was no subsequent development and listing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer pharmaceutical application of glufosfamide
  • Anticancer pharmaceutical application of glufosfamide
  • Anticancer pharmaceutical application of glufosfamide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0180] In vitro cell experiment

[0181] 1. Materials and methods

[0182] 1.1. Materials and instruments

[0183] AA8 cell line, purchased from American type culture collection (ATCC#CRL-1859);

[0184] UV41 cell line, purchased from American type culture collection (ATCC#CRL-1860);

[0185] MEM-alphamedium medium, purchased from Fisher Reagent Company (Fisher#12-561-056);

[0186] Fetal bovine serum (FBS for short), purchased from ThermoFisher (ThermoFisher#26140-079);

[0187] Penicillin streptomycin solution-double antibody Penn-step, purchased from Hyclone Company (Hyclone#SV30010);

[0188] AlamarBlue reagent was purchased from ThermoFisher (ThermoFisher #DAL1100).

[0189] 1.2. Test compound

[0190] compound

Dissolving solvent

Test concentration (μM / L)

dilute solution

Glufosfamide

DMSO

0.015-1000

Media solution containing 0.5% DMSO

Cisplatin

DMSO

0.003-200

Medium solution containing 0.5% DMSO

[0191]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Glufosfamide or analogues thereof have specific inhibitory effects on cells with specific gene variations, specifically, DNA repairs damaged cells, the cells or tissues at least have one or more genemutations of BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP or ERCC5. The analogues are esters obtained by esterification reaction of one or more hydroxyl groups in glufosfamide molecules with organic acid and inorganic oxyacid; esters obtained by esterification reaction of one or more hydroxyl groups in glufosfamide molecules with amino acid; and salts obtained by reaction of glufosfamide molecules withan acid. Therefore, provided is medical uses of glufosfamide or the analogues thereof in treatment of tumors and cancer diseases of cancer patients with specific gene variations.

Description

technical field [0001] The present invention relates to glufosfamide, especially the treatment of glufosfamide to cancer or tumor patients with specific gene mutation. Background technique [0002] Glufosfamide (glufosfamide), the chemical name is β-D-glucopyranosyl-N, N'-bis (2-chloroethyl) phosphoramide, and the English name is β-D-Glucopyranosyl-[N, N'- bis[(2-chloroethyl)]phosphoric aciddiamide, a new type of alkylating agent antineoplastic drug, is formed by linking a molecule of isophosphoramide mustard with direct alkylation and a molecule of glucose through glycosidic bonds . Glufosfamide is transported into tumor cells by the sodium-dependent glucose transmembrane transporter SAAT1, and then hydrolyzed by glucosidase to release isophosphoramide mustard to exert its activity. . [0003] The compound was first developed by Asta Medica (Degussa) in Heidelberg, Germany, in cooperation with the Cancer Research Center (DKFZ). In October 2001, Baxter International Baxt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7024A61K45/06A61P35/00A61P35/02
Inventor 段建新孟繁英李安蓉唐纳德·T·荣
Owner SHENZHEN ASCENTAWITS PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products